Published in Medical Letter on the CDC and FDA, May 16th, 2004
Company executives believe this advisory board will better enable them to go through the U.S. Food and Drug Administration and marketing requirements necessary to make the product available on a wide scale.
The company is currently speaking with various bioterrorism industry experts about potential positions with the new board and is investigating additional individuals to begin the process with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA